<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631884</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.566</article-id><article-id pub-id-type="publisher-id">ofx163.566</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nathan</surname><given-names>Ramesh V</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>John S</given-names></name><degrees>MD, FIDSA, FSHEA</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Dretler</surname><given-names>Robin H</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Luu</surname><given-names>Quyen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Metzger</surname><given-names>Brian S</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Schroeder</surname><given-names>Claudia P</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Couch</surname><given-names>Kimberly</given-names></name><degrees>PharmD, MA, FIDSA, FASHP</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Van Anglen</surname><given-names>Lucinda J</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Mazur, Statner, Dutta, </institution>
<addr-line>Nathan, PC</addr-line>, <addr-line>Thousand Oaks, California</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Knoxville Infectious Disease Consultants, P.C.</institution>, <addr-line>Knoxville</addr-line>, Tennessee</aff><aff id="AF0003">
<label>3</label>
<institution>Infectious Disease Specialists of Atlanta, P.C.</institution>, <addr-line>Decatur</addr-line>, <country>Georgia</country></aff><aff id="AF0004">
<label>4</label>
<institution>Central Georgia Infectious Diseases</institution>, <addr-line>Macon</addr-line>, <country>Georgia</country></aff><aff id="AF0005">
<label>5</label>
<institution>Austin Infectious Disease Consultants</institution>, <addr-line>Austin, Texas</addr-line></aff><aff id="AF0006">
<label>6</label>
<institution>Healix Infusion Therapy, Inc.</institution>, <addr-line>Sugar Land, Texas</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 75. Stewardship: Program Implementation</p><p>
<italic>Thursday, October 5, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S259</fpage><lpage>S259</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.566.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>IDSA guidelines for implementing an ASP were published in 2016 with required standards by The Joint Commission for hospitals beginning January, 2017. To date, no guidelines have been established in the US for ASP specific to OPAT. Using current guidelines, along with those proposed for the UK, we developed an ASP program unique to OPAT provided in US physician office infusion centers.</p></sec><sec id="s2"><title>Methods</title><p>We identified 5 core elements of the ASP pertinent to OPAT: antimicrobial use based on pathogen susceptibility, duration of OPAT, lack of <italic>C.&#x000a0;difficile</italic> infection, and no emergency department (ED) visit or hospitalization related to OPAT. Other measurable elements included initial patient (pt) education, standard order forms, labs obtained as ordered, adherence to drug stability standards and completion of OPAT as ordered. An assessment tool was developed to measure ASP compliance. Assessments were performed on 50 randomly assigned culture positive patients from each of 5 POICs receiving OPAT in&#x000a0;2016.</p></sec><sec id="s3"><title>Results</title><p>A total of 250 patients were evaluated for each of the ASP elements. Mean scores were 70.5 for core elements and 24.4 for other elements resulting in 94.9 of 100 possible. Early IV to PO conversion was documented in 8 patients resulting in a reduction of 117&#x000a0;days of&#x000a0;OPAT.</p></sec><sec id="s4"><title>Conclusion</title><p>Antimicrobial stewardship is essential in all settings of care, particularly in OPAT with extended durations of therapy. We report the first US OPAT ASP with assessment of compliance. High rates of adherence were achieved in all elements. Implementation of an ASP should be considered in all OPAT settings.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0245"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>R.&#x000a0;V. Nathan</bold>, Merck: Speaker&#x02019;s Bureau, Speaker honorarium. Allergan: Speaker&#x02019;s Bureau, Speaker honorarium. <bold>K. Couch</bold>, Merck: Speaker&#x02019;s Bureau, Speaker honorarium. Allergan: Speaker&#x02019;s Bureau, Speaker honorarium. <bold>L. J.&#x000a0;Van Anglen</bold>, Theravance: Scientific Advisor, Consulting fee</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>